Earnings call
Aurobindo Pharma Q2 FY25 earnings call
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company is on track to achieve its internal target of 21-22% EBITDA margin for the full year, with the second half expected to be better than the first half. The company expects its Penicillin G, 6-APA, Granulation and China capacity ramp-ups to drive further operational efficiencies and support growth in the coming quarter. The company recorded revenues of Rs. 7,796 crores in Q2 FY25, up 8% year-on-year and 3% quarter-on-quarter, led by strong base product sales in the US and continued growth in Europe and growth markets. The company said its next competitor was probably 33% lower in prescriptions, excluding private labels. The company has filed about 14 DMFs, of which 5 have translated into successful ANDAs in the U.S.
The numbers management gave
Results
- EBITDA in Q2 FY25 was Rs. 1,566 crores, with a margin of 20.1%, after absorbing higher R&D costs.
Show source
2 Aurobindo Pharma Limited 11 November 2024 Our EBITDA stood at Rs. 1,566 crores with a margin of 20.1% after absorbing higher the R&D costs.
- EBITDA before R&D in Q2 FY25 was 25.1%, or Rs. 1,954 crores, versus Rs. 1,936 crores in Q1 FY25.
Show source
EBITDA before R&D was 25.1% and stood at Rs. 1,954 crores versus Rs. 1,936 crores in Q1 FY25.
- Net profit for Q2 FY25 increased 8.6% year-on-year to Rs. 817 crores.
Show source
Our net profit for the quarter increased by 8.6% year-on-year to Rs. 817 crores.
- R&D expenses were higher by around Rs. 70 crores in Q2 FY25.
Show source
One is R&D expenses are higher to the tune of around Rs. 70 crores.
- The company incurred around Rs. 80 crore loss at the Pen-G plant, expected to come down partly in the coming quarter, with full breakeven by the March quarter.
Show source
Santhanam Subramanian: See, Neha, as I explained in my original speech, we have incurred around Rs. 80 crore loss which is expected to come down partly in the coming quarter and there should be fully breakeven by March quarter.
- The company produces a little over 2 billion tablets a month.
Show source
A little over 2 billion, actually, a month.
Show 7 more statements
Results
- Acrotech is steady in the range of US$ 25-30 million, and Aurobindo Pharma does not see any immediate change to that range.
Show source
So, we have given an indication earlier that Acrotech is steady in the range of US$ 25-30 million kind of range that we are talking about and we don't see any immediate change to it.
- YTD first half margin is around 20.7%, while it is maintaining its guidance of around 21%-22% EBITDA margin.
Show source
Even though the YTD first half margin is around 20.7%, we are still maintaining our guidance of around 21%-22%, right.
- The company saw volume expansion, product launches and stable pricing during Q2 FY25.
Show source
During the quarter, we witnessed volume expansion, product launches and stable pricing.
- The company recorded revenues of Rs. 7,796 crores in Q2 FY25, up 8% year-on-year and 3% quarter-on-quarter, led by strong base product sales in the US and continued growth in Europe and growth markets. Replaced by a later filing.
- Formulation business grew 11% year-on-year to Rs. 6,640 crores in Q2 FY25 and contributed around 85% of total revenue. Replaced by a later filing.
- API business was flat year-on-year at Rs. 1,156 crores in Q2 FY25, contributing around 15% of total revenue; price erosion was offset by volume gains and improved asset utilization. Replaced by a later filing.
Money and capital
- The company completed its first-ever buyback during Q2 FY25 with an outlay of US $111 million.
Show source
During the quarter, we also completed our first -ever buyback with an o utlay of US $111 million.
What it expects ahead
What management expects
- The company is on track to achieve its internal target of 21-22% EBITDA margin for the full year, with the second half expected to be better than the first half.
Show source
We are on track to achieve our internal target of 21-22% [EBITDA margin] for the full year, which means , effectively the second half should be better compared to the first half.
- The company is on course for a €900 million run rate for the current FY.
Show source
Yes, our run rate at present, as you are able to see, we are well on course for the €900 million for the current FY.
- The company is gearing up for a bare minimum of 3-4 patex Day one launches in Europe in the subsequent two financial years.
Show source
Some of them our patex Day one launches, we are gearing up for 3-4 products bare minimum.
- The company expects the first set of stockpiling effort for the customer in its CMO business to come in from late [CY]2027, with revenues expected to start trickling in then and a consistent flow of revenues from 2028 Calendar Year onwards.
Show source
With respect to the revenues and the margins and EBITs, as I told before, I hate to give guidance which is about 3 to 4 years from now but we see the first set of stockpiling effort for the customer coming in from late [CY]2027 which means the revenues will start to trickle in and we expect the consistent flow of revenues to happen from 2028 Calendar Year onwards.
- The company expects its CMO business to be no less than a 50% margin business.
Show source
And, right now, what I expect is this CMO business would not be less than a 50% margin business.
- The company is confident of completing recruitment of all patients for its biosimilar to Xolair, omalizumab, by February-March 2025.
Show source
But we are c onfident of completing the recruitment of all patients by February -March 2025.
Show 18 more statements
What management expects
- The company expects the commercial impact of its first set of Biosimilars to start in CY 2025, with key products including Denosumab and Omalizumab coming into the market from CY 2026; it expects the supply chain to stabilize in CY 2026-27.
Show source
So, you will see a commercial impact of our first set of Biosimilars starting [CY] 2025 and from [CY] 2026 you will see the key products, which is the Denosumab, Omalizumab etc. coming into the market. [CY] 26-27 would be the years that I think the supply chain would get stabilized and you will start to see how this impacts the overall numbers of the company.
- The company expects commercial impact from its Omalizumab product starting CY 2026; it plans to launch the product in India next year and in Europe in CY 2026.
Show source
Again, the commercial impact of this product will be felt starting [CY] 2026.
- The company expects its three other Biosimilars already filed in Europe to be commercialized in the next 6-7 months, if there are no other regulatory hiccups.
Show source
The three other Biosimilars that we have already filed in Europe, if there are no other regulatory hiccups, I'm expecting them to be commercialized in the next 6-7 months time in Europe.
- The company is still on track to file its first product, a trastuzumab biosimilar, in the U.S. this quarter; if approved, commercial impact from the U.S. could begin in late 2025 Calendar Year or CY 26.
Show source
In fact, I told you that the first filing will be done in this quarter, which I think we are still on track to filing our first product, which is a trastuzumab biosimilar this quarter in the U.S. And if that gets approved and you know how things happen with the U.S., it takes its own sweet time, then you can see even commercial impact from the U.S. kicking in from late 2025 Calendar Year or [CY] 26.
- The company expects launches from Eugia-II to ramp up from H2 onwards, but expects no meaningful launches in the next 6 months or next 1 year.
Show source
But there are no meaningful launches in next 6 months or next 1 year.
- The company expects to achieve break-even in the Penicillin G product facility by Q4 FY25 and for it to start contributing positively from FY26 onwards.
Show source
We expect to achieve break-even in the Penicillin G product facility by Q4 FY25 and start contributing positively from FY26 onwards.
- The company expects its increased Red Sea-related costs to come down between Q2 FY25 and the next quarter.
Show source
Between this quarter and next quarter, it will come down.
- The company expects contribution from the Pen-G plant to start next year onwards.
Show source
So, you can start seeing the contribution from this plant from next year onwards.
- The company expects standard new launches in Europe, including products new to the relevant country, to add to its portfolio in the subsequent two financial years.
Show source
Plus, the standard set of new launches, new to that country, at the same time which will add to the portfolio.
- The company is looking forward to substantial Eugia launches in Europe in year two and CuraTeQ launches.
Show source
In addition, of course, the Eugia launches which are substantial in the year two and also we are keenly looking forward to the CuraTeQ launches coming up.
- The company expects sales and EBITDA in the second half to be much better than in the first half.
Show source
Santhanam Subramanian: Sales and EBITDA are expected to be much better than the first half in the second.
- The company expects Denosumab to be commercial in Europe in CY2026.
Show source
So, I think, Denosumab would be commercial in the CY2026 in Europe.
- The company strives to make Denosumab commercial and available to Indian patients in the next year.
Show source
And in India, we strive to make it commercial and make it available to the Indian patients in the next year itself.
- The company expects to file its Omalizumab product with EMA and FDA by the end of next year.
Show source
This means, based on my earlier guidance, we can still have a chance of filing this product by the end of next year with EMA and also with the FDA.
- The company expects its initial biosimilar opportunities to come from India, Europe and the rest of the world, with the U.S. taking a backseat initially.
Show source
So, towing in the line that you have stated, the initial opportunity would essentially come from Europe and India and the rest of the world with U.S. taking a backseat.
- The company expects to steadily maintain the Acrotech business, with possible minor improvements but nothing significant in the short term.
Show source
We will be steadily maintaining this business or there could be some minor improvements but nothing significant that we are looking at immediately in the short term.
- The company expects the second half to be better than the first half, including all businesses, with Eugia and Penicillin-G expected to move forward with better operations/contribution.
Show source
We expect the second half will be better than the first half, including all businesses.
- The company anticipates normalization of its net debt position over the course of the year. Replaced by a later filing.
Show source
We anticipate a normalization of our net debt position over the course of the year, further strengthening our balance sheet.
What it is building and selling
Projects and capacity
- The company expects its Penicillin G, 6-APA, Granulation and China capacity ramp-ups to drive further operational efficiencies and support growth in the coming quarter.
Show source
We are actively ramping up the capacities in Penicillin G, 6-APA, Granulation and China, which will drive further operational efficiencies and support our growth objectives in the coming quarter.
- CMO arm, TheraNym Biologics, has capital expenditure guidance of around ₹1,000 crores for the current capacities projected with 2x15 KL Mammalian cell culture Bioreactor Lines and associated Purification Line.
Show source
I don't know if I understood your question well but with respect to the CapEx in the TheraNym Biologics, our CMO arm, we alluded to around ₹1,000 crores as guidance before and that remains the guidance with the current capacities that we are projecting with 2x15 KL Mammalian cell culture Bioreactor Lines and associated Purification Line.
- The company is considering adding two more 15 KL Bioreactor Lines at the TheraNym Biologics site; the decision is yet to be taken.
Show source
So, that decision is yet to be taken.
- If Aurobindo Pharma Limited decides to add two more 15 KL Bioreactor Lines at the TheraNym Biologics site, the addition would increase current capital expenditure guidance by another US$ 40-$50 million.
Show source
If that decision is taken, then it would add to the current capital expenditure guidance by another US$ 40-$50 million.
- Pipeline has three glucagon like Peptide-1 Receptor Agonists, and the company is investing in expanding its manufacturing capacity footprint.
Show source
Right now, our pipeline has three glucagon like Peptide-1 Receptor Agonists with us now investing in expanding our manufacturing capacity footprint.
- The company has about 5 manufacturing lines capable of producing gram quantities to a kg quantity of peptide product.
Show source
Right now, we have about 5 manufacturing lines which can do gram quantities to a kg quantity of the product.
Show 11 more statements
Projects and capacity
- The company has initiated constructing or commissioning Phase-I of a new GLP facility, expected to be ready by the end of next year, with a minimum of 100 kg capacity and scope to expand in Phase-2 and Phase-3 to another 400 kilograms of GLP-1 APIs.
Show source
But considering the anticipated demand for the GLP-1 products, we have initiated constructing or commissioning a Phase-I of the new GLP facility, which I believe would be ready by the end of next year, and this would catapult us into a minimum of 100 kg capacities with the scope to expand it in Phase-2 and Phase-3 to another 400 kilograms of GLP-1 APIs that we can produce.
- The company is on track to complete its Denosumab Phase-3 clinical study in women with post-menopausal osteoporosis by May or June, 2025; recruitment of all 436 patients across Europe is complete.
Show source
We are on track to complete our Denosumab Phase-3 clinical study in women with post-menopausal osteoporosis by May or June, 2025.
- Recruitment for its biosimilar to Xolair, omalizumab, has been slower by 3-4 months than anticipated.
Show source
Likewise, with our Biosimilar to Xolair, which is omalizumab, I must admit that our recruitment has been slower by 3-4 months than anticipated.
- The company is thinking about adding capacity at its Mammalian cell culture facility, which it is already building, to be ready for opportunities starting CY 2028; building capacities of this scale in Mammalian cell culture takes about 2-2.5 years.
Show source
So, we thought instead of reacting to a requirement maybe 2-3 years down the line, why not add capacities as we build the block one of this facility that we are already building and hence be ready for any opportunities that come our way starting [CY] 2028.
- The company says the capacity at its Mammalian cell culture facility will be the largest available in India, and that no one in the country has done anything over 10,000 liters mammalian.
Show source
No one had done anything over 10,000 liters mammalian in the country.
Demand and pricing
- The company said its next competitor was probably 33% lower in prescriptions, excluding private labels.
Show source
And we are number one in terms of prescriptions, the next competitor is probably 33% lower, if I see in terms of prescription.
- The company sees a market opportunity in Europe and FDA [US] for omalizumab, where it would be one of three or four players.
Show source
So, as I told in one of the Earnings Call before, I'm looking at a market opportunity in both Europe and FDA [US] where I would be one of the three or four players for omalizumab.
- Price erosion in Aurobindo Pharma's existing products is in the low single digits, a trend for the last few quarters.
Show source
Yugandhar Puvvala: Yes, price erosion is in a low single digits.
Segments
- The company has filed about 14 DMFs, of which 5 have translated into successful ANDAs in the U.S.
Show source
We have filed about 14 DMFs, out of which I think 5 of them have translated into successful ANDAs in the U.S. We continue to streamline our portfolio with more focus on oncology and primarily the diabetes market.
- The company is starting to make a foray into the domestic market with Peptides.
Show source
Likewise, we are also starting to make some foray into the domestic market with Peptides.
- The company received approval for a first-in-class Linaclotide Peptide used in irritable bowel syndrome.
Show source
We have received an approval for a first -in-class Linaclotide Peptide, which is used in irritable bowel syndrome.
Risks, rules and outside factors
Outside factors
- Carriage outwards increased by Rs. 30 crores in Q2 FY25 because of Red Sea-related issues, and it moved material by air to avoid penalties.
Show source
We have an increased carriage out wards to the tune of Rs. 30 crores on account of the Red Sea related issues.
Everything else said on the call
What management stressed
- The company is not going for any big bang investments in brands now.
Show source
We are not going for any big bang investments now in terms of brands.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Kunal Dhamesha: Thank you for taking my question and thank you for providing details, Subbu sir. One question on the Penicillin-G front. What progress are we making in terms of taking commercial batches and on the yield front ? You suggested that you would provide some updates in the Quarter 3 call.
Answer, santhanam subramanian
Santhanam Subramanian: Yes. So, we are now taking the commercial batches. We have taken around nearly 35 batches in Q2. Now we have accelerated the entire thing and we should be doing not less than 35 to 40 batches for the current month alone. And we will be accelerating this. While, we have taken care of everything, the headwind which we have been facing is on account of the Indian climatic conditions, which we have understood well and have sorted out. And this will help us to accelerate the production ramping up in the coming quarters.
Answer, santhanam subramanian
That is the reason we said we are estimating to achieve a breakeven in Q4, and probably we may achieve half of it in the current quarter.
Question
Kunal Dhamesha: Sure. And sir, whatever we are producing currently, is also being used within our products, or we are still to use those?
Answer, santhanam subramanian
Santhanam Subramanian: No, whatever we have produced so far, we have been converting into 6-APA comfortably without any hiccups.
Question
Kunal Dhamesha: Okay. And then it is going into our products?
Answer, santhanam subramanian
Santhanam Subramanian: Yes, it's going into our products. We are also giving samples to third parties, on which we have been taking their feedback and then doing various tests relating to the product.
Question
Kunal Dhamesha: Okay. Thank you, Sir. And one more on the US business. While you have suggested that the core business has kind of done well and the pricing remains kind of neutral, on the volume growth that we are seeing, can you maybe quantify what type of volume growth? Is it like in low single digit range or mid-single digit range on volume growth? And are there any particular pockets of therapies, etc., where we are seeing this growth, or is it more broad based? Any particular channel that has opened up to us, which was not there earlier?
Answer, swami iyer
Swami Iyer: I'll take this question, Subbu. Thanks, Kunal, for this question. US business has grown in terms of volume. We have touched certain good milestones this quarter. And there has been growth quarter-to-quarter and of course, on an annual basis. So, the major reason 5 Aurobindo Pharma Limited 11 November 2024 for the volume increase is due to the introduction of newer launches. And of course, in our base business also, we have seen some traction.
Question
Kunal Dhamesha: Sure. Sir, but this is because some players are moving out. What are you seeing on the ground as of now? Is it some players moving out, creating the vacuum, or are we moving to new channels?
Answer, swami iyer
Swami Iyer: Yes. So, now primarily, I don't see players going out as being the reason , because that's been there. It's been there, even 1–1½ years back, some major companies had started going out. And later, some more companies also moved out of a few products. We have been seeing it, but it's nothing dramatic. The major reason, of course, we mentioned earlier, maybe about four or five earnings calls prior to this that we have planned to launch 40 products. We were bang on.
Answer, swami iyer
40 products we launched, and those are all getting converted now into volumes and sales, that's one. Some of our existing business, we have been able to get a little more business because of reliability of supply, thanks to our deep manufacturing ability and supply chain. And of course, the US team has done very well in terms of converting leads to orders. So, these are the primary reasons. And in terms of different forms that, you see, we talk about the tablets, we don't talk about the liquids or anything else in terms of tablets, not so much. We just take that as one unit. So, there's no change due to th e different form of presentation.
Question
Kunal Dhamesha: Sure. And if I may, one last one? The specialty injectable sales, which has kind of declined 11%, roughly from US$ 102 million to US$ 81 million, I think Subbu sir alluded that there was a special product which kind of did not do well in this quarter. So, one, what are our expectations from Quarter 3? And also, you alluded to the supply chain issues. So, is it related to rebooting of Eugia-III, or there is something else which is going on here? And when can we expect the supply chain issues to resolve?
Answer, yugandhar puvvala
Yugandhar Puvvala: Yes. Kunal, I think you asked the question, you also answered it. So, you’re right. We are scaling up Eugia-III back to the normal levels, and it is already coming to the stabilization phase. Quarter 1 and Quarter 2, both quarters, we were actually taking a lot of corrective actions. That is why the supplies were a bit lower than the normal levels. That is why we had to have this bit of a degrowth.
Answer, yugandhar puvvala
It is mainly related to the supply chain issues from Eugia-III. Kunal Dhamesha: Okay. So, there is US$ 102mn falling to US$ 81mn , is it a factor of just supply chain issue or there is the issue of the lumpy product or the special product?
Answer, yugandhar puvvala
Yugandhar Puvvala: No, it is combination of both. Because obviously, we cannot really do quarter-to-quarter management of that lumpy product. So, Q2 and Q3 is expected to be lower for the special product, whereas half of it is mainly related to Eugia-III supply issues.
Question
Shyam Srinivasan: Good morning. Thank you for taking my question. Just two quick ones. First is on the R&D cost, Rs. 410 crores, it is kind of jumped up like 80 to 100 basis points. So, I just want to understand what is driving the higher R&D? And if you could also split us out, maybe based on the different segments on where is this incremental spend going to? That's question one. And just question two is, Subbu sir, just the ETR for the quarter was kind of high. So, is there something that's happening there that we need to be aware of? If you could give us a full year ETR guidance. Thank you.
Answer, santhanam subramanian
Santhanam Subramanian: First question will be answered by Yugandhar and I'll address the tax later. Not Yugandhar, I'm sorry. Dr. Satakarni.
Answer, satakarni makkapati
Satakarni Makkapati: Hi Shyam. With respect to the escalation of the R&D cost that you guys witnessed in our quarterly update, majority of these costs are a result of the Phase 3 clinical trials expenditure for four of our Biosimilar products. As you know, we have Denosumab, a biosimilar to Prolia, which is in Phase 3 clinical trials across multiple countries in Europe. We have Omalizumab, a biosimilar to Xolair, which is also going through an active Phase 3 clinical trial recruitment in chronic urticaria patients. So, that's a critical spend for us. Then we have an oncology product biosimilar to Avastin, which is closing on the recruitment milestone. I think we just have about another 70 subjects out of 650 odd subjects that we have to recruit.
Answer, satakarni makkapati
And then we have an ophthalmic product, which is also in Phase 3 clinical trial across India, Europe and CIS countries. So, when the programs are reaching their logical end in terms of the clinical trial recruitment, that's when, based on the milestone payments that we decided with the clinical CROs, you tend to spend more. And we are in that phase. And the guidance on this pattern of spending will continue for about at least four quarters before the clinical study reports and the filings would happen in the regulated markets. So, you will see this spend, this pattern of spend, at least for the four quarters, Shyam. Does that answer your question?
Question
Damayanti Kerai: Hi, good morning. My first question is again on generic injectables in the US. So, you mentioned in 1st and 2nd Quarter, already corrective steps are taken, and now things are broadly stabilizing. So, in terms of numbers, if you can say how much recovery we have seen compared to pre-disruption level? And should we assume it to normalize, say by 4th Quarter? And do you maintain your guidance for global Eugia sales for this year?
Answer, yugandhar puvvala
Yugandhar Puvvala: Hi, Damayanti. Yes, we have taken the hit in Q1, Q2. And in fact, if you see it, we have increased our sales from Q1 to Q2 and expect Q3 and Q4 to be even better from a pure generic injectable basis. So, we are bang on in terms of Q4 is expected to be the best quarter. And that is our expectation at this point of time. And the worst is over with respect to Eugia-III is concerned. We have completed all our remediation actions.
Question
Damayanti Kerai: Sure. And just want to understand, do you need another inspection by the FDA, or it's like partly from you and remediations are done and then things can go back to normal level?
Answer, yugandhar puvvala
Yugandhar Puvvala: So, from a perspective of continuing to supply existing products, it's over . In terms of, we do not expect any further thing required from Eugia management. And we already had a detailed discussion with FDA on this. So, existing products will continue to be supplied without any disruptions going forward as well. And we never had issues, it was our voluntary decision to slow down production, but FDA never asked us to do anything. And for the approval of new products, we feel a new inspection is required. So, FDA has asked us .
Answer, yugandhar puvvala
As and when we are ready, we can invite them for a re -inspection.
Question
Damayanti Kerai: Okay. 3Q of FY26. And my second and last question is for Mr. Swami Iyer. Just want to understand, what are your expectations on US business after the Presidential Election in the US? So, very broadly, what are you hearing and how do you think a company like Aurobindo can see more business ? Because focus is again on the affordable healthcare medicines .
Answer, swami iyer
Swami Iyer: Yes, sure. We feel, at this point, maybe it's a little early to say what's going to happen. But we do not see any issues as far as any change in policy is concerned. For example, you know, we have a very good manufacturing base in India and we are able to meet the 8 Aurobindo Pharma Limited 11 November 2024 requirement to be one of the low-cost manufacturers. So, that way, we have the ability to grow our business in case there are any cost considerations. Now, as far as the manufacturing in the US is concerned, if that becomes a requirement for some kind of products or if there is any norm that comes up from the government, we are ready to meet that too because we have a facility in Dayton, which is scalable. And then we also, as you know, a facility in Puerto Rico that can be quickly brought online and then we can start commercial production.
Answer, swami iyer
So, we do not foresee a problem. But it will be better not to speculate and wait for the next 2-3 months to get a better understanding.
Show 19 more questions
Question
Yash Darak: Thank you for the opportunity. Just a few questions. As far as the employee expenses are concerned, there has been a huge increase in your expenses. Will we see this as a normal run rate of expenditure, or it will be brought down?
Answer, santhanam subramanian
Santhanam Subramanian: No, employee expenses is normal because, Yash, if you really see, the European currency has moved up . And when we translate the existing things, it appears to be more, but it is normal only. It's in line with our plans.
Question
Yash Darak: And on the other expenses?
Answer, santhanam subramanian
Santhanam Subramanian: Other expenses, we talked about it . In the call itself we have talked about it. One is R&D expenses are higher to the tune of around Rs. 70 crores. We have an increased carriage out wards to the tune of Rs. 30 crores on account of the Red Sea related issues. So, we need to move quickly to avoid any penalties, et c. We have to move the material through air. And overall, because of the overall environment prevailed in the Red Sea, the entire cost has gone up, which we think it will come down now. Between this quarter and next quarter, it will come down.
Question
Yash Darak: When do you expect it to reduce?
Answer, santhanam subramanian
Santhanam Subramanian: Yes. As Dr. Satakarni has said, R&D costs are likely to continue for another 3-4 quarters. In terms of the freight cost, it is expected to slow down in this quarter and the next quarter. But let's see. I mean, if there is a change in overall approach. Let's wait and see what's going to happen.
Question
Yash Darak: Okay. Another question. So, another question regarding other income. So, the other income in June was around Rs.221 crores, which is now reduced to somewhere around Rs. 136. Is this a normal run rate for other income?
Answer, santhanam subramanian
Santhanam Subramanian: No, you take the normal run rate around, I think if I am right this quarter we incurred, [other expenses of] Rs. 1,900 crores. You can take anywhere between Rs. 1,850 to Rs. 1,900 crores. 9 Aurobindo Pharma Limited 11 November 2024 In terms of the other income is around 120-125 crores will be there. But it will go down slightly, because if you really see the interest rates have been coming down. So, both our interest expenditure will come down and the other income also will come down. Because the other income is predominantly represented by the interest income on the deposits we make in U.S. and Europe. Yash Darak: Thank you, Sir.
Answer, santhanam subramanian
Santhanam Subramanian: It is it is already operational. We are doing ramping up in a phased manner which is expected to accelerate this quarter and next quarter.
Question
Neha Manpuria: Yes, thanks for taking my question. Subbu Sir, on the Pen -G plant now that we accelerate the ramp up, is it fair to assume that the captive consumption and the gross margin improvement should be meaningfully higher in the second half or would that be visible probably mostly in Fiscal 26?
Answer, santhanam subramanian
Santhanam Subramanian: See, Neha, as I explained in my original speech, we have incurred around Rs. 80 crore loss which is expected to come down partly in the coming quarter and there should be fully breakeven by March quarter. So, you can start seeing the contribution from this plant from next year onwards.
Question
Neha Manpuria: Okay. And you're saying both of these, the captive consumption and external sales, will be Fiscal 26.
Answer, santhanam subramanian
Santhanam Subramanian: Captive consumption already taking place. 10 Aurobindo Pharma Limited 11 November 2024 Neha Manpuria: Okay, got it.
Question
And my second question is on the European business, Murali Sir, we are already clocking close to the €900 million mark that you mentioned last quarter. Last quarter and third quarter, we'd seen a clawback tax. So, should we factor in something like that in this quarter also? And from this €900 million base if I think about Fiscal 26 and 27, what do you think are the growth drivers that I should build in for the European business scaling up from the current level.
Answer, v muralidharan
V. Muralidharan: Yes, Neha, good morning to you and good morning to everyone and thank you for raising this question. Yes, our run rate at present, as you are able to see, we are well on course for the €900 million for the current FY. And also the growth drivers for the subsequent two financial years are going to be more launches. Some of them our patex Day one launches, we are gearing up for 3-4 products bare minimum. Some of them are risk- based, still we are assessing, but this is going to contribute. Plus, the standard set of new launches, new to that country, at the same time which will add to the portfolio. In addition, of course, the Eugia launches which are substantial in the year two and also we are keenly looking forward to the CuraTeQ launches coming up.
Answer, v muralidharan
So, these will be the main growth drivers. At the same time, already we are pushing a billion dollar mark and we will be going well past that in the coming years.
Question
Neha Manpuria: So, the billion dollar next year itself or should I take that as an… V. Muralidharan: Yes, I meant billion dollar.
Answer, v muralidharan
We are already at €900 million, which is almost a notch above in dollars.
Question
Neha Manpuria: Okay. So, in terms of the growth rate, next year would be similar to the growth that we have seen this quarter or our usual fiveish percent that we see for European business?
Answer, v muralidharan
V. Muralidharan: Yes. See, the European [industry] business, growth is rather muted. It is in the flat or low single digit, whereas we'll be always tracking towards high single digit or double digit marks. We are confident of that.
Question
Jigar Walia: Okay, got it. And any overall guidance for the second half for sales EBITDA?
Answer, santhanam subramanian
Santhanam Subramanian: Sales and EBITDA are expected to be much better than the first half in the second.
Question
Jigar Walia: Got it. One question, if I can take for Dr. Satakarni. So, in the case of total CapEx, which is now been done in Merck JV right now and if at all there is something around in terms of EBITDA margin or value type of perspective from a slightly longer term perspective, if you can provide? Dr. Satakarni Makkapati: Hello, Jigar.
Answer, satakarni makkapati
I don't know if I understood your question well but with respect to the CapEx in the TheraNym Biologics, our CMO arm, we alluded to around ₹1,000 crores as guidance before and that remains the guidance with the current capacities that we are projecting with 2x15 KL Mammalian cell culture Bioreactor Lines and associated Purification Line. But there is also a thought process that we would like to maximize our capacity footprint in that site by addition of two more 15 KL Bioreactor Lines. So, that decision is yet to be taken. If that decision is taken, then it would add to the current capital expenditure guidance by another US$ 40-$50 million. With respect to the revenues and the margins and EBITs, as I told before, I hate to give guidance which is about 3 to 4 years from now but we see the first set of stockpiling effort for the customer coming in from late [CY]2027 which means the revenues will start to trickle in and we expect the consistent flow of revenues to happen from 2028 Calendar Year onwards. And, right now, what I expect is this CMO business would not be less than a 50% margin business. I would like to leave it there and not speculate too much, Jigar, if that is okay with you.
Question
Tarang Agarwal: Sure. And last question on the U.S. business, what would be in your view a good base for the oral solids. [And also on OTC business] That seems to be flat at about US $25 million.
Answer, swami iyer
Swami Iyer: Fairly high level of dollar value and even volume. We are at 2 billion tablets a month. A little over 2 billion, actually, a month. And we are number one in terms of prescriptions, the next competitor is probably 33% lower, if I see in terms of prescription. This is not even considering the private labels. The reason why I'm telling you this is, we have a fairly large base and adding substantially to this base requires new product, newer form of presentation. We are working on it.
Question
Nitin Agarwal: Sir, both, if you can. In terms of, you've talked about 14 DMFs, there is mention of GLP additional capacities. So, what kind of opportunity do we see here for both the segments?
Answer, satakarni makkapati
In peptides, as you know, for over a decade at Aurobindo we have carefully nurtured capabilities in both solid state and liquid phase Peptide synthesis. We have filed about 14 DMFs, out of which I think 5 of them have translated into successful ANDAs in the U.S. We continue to streamline our portfolio with more focus on oncology and primarily the diabetes market. Right now, our pipeline has three glucagon like Peptide-1 Receptor Agonists with us now investing in expanding our manufacturing capacity footprint. Right now, we have about 5 manufacturing lines which can do gram quantities to a kg quantity of the product. But considering the anticipated demand for the GLP-1 products, we have initiated constructing or commissioning a Phase-I of the new GLP facility, which I believe would be ready by the end of next year, and this would catapult us into a minimum of 100 kg capacities with the scope to expand it in Phase-2 and Phase-3 to another 400 kilograms of GLP-1 APIs that we can produce. Likewise, we are also starting to make some foray into the domestic market with Peptides. We have received an approval for a first -in-class Linaclotide Peptide, which is used in irritable bowel syndrome.
Question
But in terms of meaningful commercial impact of these projects, by when do you start seeing that happening? Dr. Satakarni Makkapati: So, with respect to our Biosimilars initiative, as I told that, we have four products in the global Phase-3 clinical trials.
Answer, satakarni makkapati
We are on track to complete our Denosumab Phase-3 clinical study in women with post-menopausal osteoporosis by May or June, 2025. In fact, we completed the recruitment of all 436 patients across Europe. So, I think, Denosumab would be commercial in the CY2026 in Europe. And in India, we strive to make it commercial and make it available to the Indian patients in the next year itself. Likewise, with our Biosimilar to Xolair, which is omalizumab, I must admit that our recruitment has been slower by 3-4 months than anticipated. This is expected in the dermatology setting sometimes depending on how the sites operate in Europe. But we are c onfident of completing the recruitment of all patients by February -March 2025.
Answer, satakarni makkapati
This means, based on my earlier guidance, we can still have a chance of filing this product by the end of next year with EMA and also with the FDA. This product, as you know, Nitin will be a very interesting opportunity for us considering its use in chronic urticaria, respiratory asthma and accidental food allergies. So, as I told in one of the Earnings Call before, I'm looking at a market opportunity in both Europe and FDA [US] where I would be one of the three or four players for omalizumab. Again, the commercial impact of this product will be felt starting [CY] 2026. In India, we plan to launch it next year but in Europe it will be [CY] 2026. The three other Biosimilars that we have already filed in Europe, if there are no other regulatory hiccups, I'm expecting them to be commercialized in the next 6-7 months time in Europe. So, you will see a commercial impact of our first set of Biosimilars starting [CY] 2025 and from [CY] 2026 you will see the key products, which is the Denosumab, Omalizumab etc. coming into the market. [CY] 26-27 would be the years that I think the supply chain would get stabilized and you will start to see how this impacts the overall numbers of the company.
Question
Nitin Agarwal: Sir, if I push that little forward, so whatever that you've discussed, it is fair to say that most of our opportunity in the initial years is going to be around India and Europe and U.S. will probably begin to contribute later in a meaningful way? Dr. Satakarni Makkapati: I think that is a fair assessment of the business.
Answer, satakarni makkapati
The initial opportunities will come from India, Europe and the rest of the world. U.S., I'm expecting my first filing. In fact, I told you that the first filing will be done in this quarter, which I think we are still on track to filing our first product, which is a trastuzumab biosimilar this quarter in the U.S. And if that gets approved and you know how things happen with the U.S., it takes its own sweet time, then you can see even commercial impact from the U.S. kicking in from late 2025 Calendar Year or [CY] 26. But I would exercise some caution with how the USFDA reviews of the GMP facilities and the dossier goes on. So, towing in the line that you have stated, the initial opportunity would essentially come from Europe and India and the rest of the world with U.S. taking a backseat. But U.S. would also kick in; that's where the business is. Hopefully, in CY 26-27.
Question
Sir, on the CMO business, what is the thought process for adding additional capacities? And what will drive the decision for you to go ahead or not go ahead with it? Dr. Satakarni Makkapati: So, we would like to add additional capacities in that facility, Nitin, to essentially give us more flexibility so that in case there is a ramping up requirement from the customer, then we are not caught up napping because it takes about 2-2.5 years to build capacities of this scale in Mammalian cell culture.
Answer, satakarni makkapati
And as I told before, this will be the largest capacity that will be available in India. No one had done anything over 10,000 liters mammalian in the country. So, we thought instead of reacting to a requirement maybe 2-3 years down the line, why not add capacities as we build the block one of this facility that we are already building and hence be ready for any opportunities that come our way starting [CY] 2028. So that's the reason why we are thinking about adding capacities there, Nitin.
Question
Ankush Mahajan: Yes, Sir. Yes, Sir. So, what is the price erosion in the existing products? And what is the strategy for the new launches from the Eugia -II?
Answer, yugandhar puvvala
Yugandhar Puvvala: Yes, price erosion is in a low single digits. That's been the trend for the last few quarters. And launches are a bit low this year but we expect things to ramp up from H2 onwards. But there are no meaningful launches in next 6 months or next 1 year. So, it is more about supplying from our existing molecules and see how things pan out in the next 6 months.
Question
Amey Chalke: Yes, the spectrum portfolio which we have acquired. 17 Aurobindo Pharma Limited 11 November 2024 Swami Iyer: Right-right.
Answer, swami iyer
So, we have given an indication earlier that Acrotech is steady in the range of US$ 25-30 million kind of range that we are talking about and we don't see any immediate change to it. We also indicated the strategy behind this. We are not going for any big bang investments now in terms of brands. So, that's where we are. We will be steadily maintaining this business or there could be some minor improvements but nothing significant that we are looking at immediately in the short term.
Question
Amey Chalke: Sure, sure. The second question I have is on margins. This might be repeated as I was not there in the opening part. We have seen impact of higher R&D, the Pen-G losses and also the Revlimid or the specialty product lower sales. Despite that, our margins have been bit healthy around 20%, is there anything which management wants to highlight or, Subbu Sir, you want to highlight? Or should we consider this 20% of the base going ahead?
Answer, santhanam subramanian
Santhanam Subramanian: No, I think, I explained it very well at the beginning itself. Even though the YTD first half margin is around 20.7%, we are still maintaining our guidance of around 21%-22%, right. We expect the second half will be better than the first half, including all businesses. As Yugandhar rightly explained on the Eugia and the Penicillin-G, it's expected to move forward with the better operations/contribution. With all these things, we still maintain the 21%-22% [EBITDA margin].
Questions about this call
- When was the Aurobindo Pharma Q2 FY25 earnings call transcript filed?
- Aurobindo Pharma filed the transcript with the exchange on 18 Nov 2024. This page is built from that transcript.
- What does this page list?
- 56 statements from the transcript across 8 topics, 37 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 29 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.